Paraplatin

Links shared publicly online about this topic

Two Combination Treatment Regimens Added To Updated NCCN Guidelines For Ovarian Cancer

medicalnewstoday.com — “The national comprehensive cancer network (nccn) recently updated the nccn clinical practice guidelines for oncology™ for ovarian cancer to reflect the addition of two preferred combination View full resource at medicalnewstoday.com

  • View Related
  • Share

Most Recently Shared on January 27, 2010 at 6:37 am By:

medical_tweets medical_tweets Health News

Two Combination Treatment Regimens Added To Updated NCCN Guidelines For Ovarian Cancer The National Comprehensive Can.. http://bit.ly/almLHB

2 years ago...

Medical News: ECCO-ESMO: Combo Looks Good for Later Breast Cancer Tx - in Meeting Coverage, ECCO-ESMO from MedPage Today

medpagetoday.com — “STOCKHOLM -- Adding the PARP inhibitor iniparib to gemcitabine (Gemzar) plus carboplatin (Paraplatin) may benefit triple-negative metastatic breast cancer patients when used as second- or third-line tView full resource at medpagetoday.com

  • View Related
  • Share

Most Recently Shared on September 29, 2011 at 9:53 pm By:

MedicalNews Medical News Health News

ECCO-ESMO: Combo Looks Good for Later Breast Cancer Tx (CME/CE) http://t.co/oB0QBkVq

8 months ago...

ESMO: IPASS Data Show No Survival Benefit for Gefitinib (CME/CE) - QualityPoint Technologies

qualitypointtech.net — “MILAN (MedPage Today) -- Final results of the IRESSA Ran Asia Study (IPASS) failed to show any difference in overall survival between patients with advanced non-small cell lung cancer treated with gefitinib (Iressa) or carboplatin (Paraplatin) and paclitaxel (Taxol) chemotherapy, researchers said here.View full resource at qualitypointtech.net

  • View Related
  • Share

Most Recently Shared on October 11, 2010 at 9:24 pm By:

MedicalFeed MedicalFeed Health News Feed

ESMO: IPASS Data Show No Survival Benefit for Gefitinib (CME/CE): MILAN (MedPage Today) -- Final results of the IR... http://bit.ly/dCHVOt

2 years ago...

The Top 3 resources shared on this topic. More resources.

Key stats and trends about this topic

Featuring the top 3 experts for this topic

Advertisement

Share via Email

Share this WisdomCard with others by embedding on your site or blog.

300x260

425x300

560x390